Triprolidine Hydrochloride Syrup
NDC 69367-253
Product Information
Triprolidine Hydrochloride is a OTC MONOGRAPH DRUG-approved product labeled by Westminster Pharmaceuticals, Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a syrup for oral administration. This product entry covers the primary NDC 69367-253 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 69367-253?
What are the uses of this product?
What are Active Ingredients of this product?
- TRIPROLIDINE HYDROCHLORIDE .938 mg/mL - Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TRIPROLIDINE HYDROCHLORIDE (UNII: YAN7R5L890)
- TRIPROLIDINE (UNII: 2L8T9S52QM) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- GLYCERIN (UNII: PDC6A3C0OX)
- METHYLPARABEN (UNII: A2I8C7HI9T)
- AMMONIUM GLYCYRRHIZATE (UNII: 3VRD35U26C)
- POTASSIUM CITRATE (UNII: EE90ONI6FF)
- POTASSIUM SORBATE (UNII: 1VPU26JZZ4)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- PROPYLPARABEN (UNII: Z8IX2SC1OH)
- WATER (UNII: 059QF0KO0R)
- SUCRALOSE (UNII: 96K6UQ3ZD4)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1491649 - triprolidine HCl 0.938 MG in 1 mL Oral Solution
- RxCUI: 1491649 - triprolidine hydrochloride 0.938 MG/ML Oral Solution
* Please review the full disclaimer at the bottom of this page.